DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/2ff92m/cytomegalovirus) has announced the addition of the "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- 3-V Biosciences, Inc.
- AIMM Therapeutics B.V.
- AlphaVax, Inc.
- Altor BioScience Corporation
- Applied Immune Technologies Ltd
- Astellas Pharma Inc.
- BioApex, s.r.o.
- Bionor Pharma ASA
- Biotest AG
- CAP-CMV GmbH
- Cell Medica Limited
- Chimerix, Inc.
- GlaxoSmithKline plc
- Hookipa Biotech AG
- Humabs BioMed SA
- INAGEN ApS
- iQur Ltd.
- Kadmon Corporation, LLC
- Lead Discovery Center GmbH
- Merck & Co., Inc.
- Microbiotix, Inc.
- Novartis AG
- Pfizer Inc.
- Phoenix Biotechnology, Inc.
- Spider Biotech
- Trellis Bioscience, Inc.
- Vakzine Projekt Management GmbH
- VBI Vaccines Inc.
-
Vical Incorporated
For more information visit http://www.researchandmarkets.com/research/2ff92m/cytomegalovirus
